Plus Therapeutics (NASDAQ:PSTV) Issues Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Plus Therapeutics (NASDAQ:PSTV) announced its quarterly earnings results on Friday. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.20), FiscalAI reports. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.97 million.

Plus Therapeutics Stock Down 8.9%

Plus Therapeutics stock opened at $5.25 on Friday. Plus Therapeutics has a 52 week low of $2.90 and a 52 week high of $23.42. The company’s 50 day moving average price is $5.84 and its two-hundred day moving average price is $9.42. The stock has a market cap of $36.02 million, a P/E ratio of -2.28 and a beta of 1.40.

Hedge Funds Weigh In On Plus Therapeutics

Several hedge funds have recently modified their holdings of the company. L1 Global Manager Pty Ltd bought a new position in shares of Plus Therapeutics during the 4th quarter worth approximately $1,167,000. Geode Capital Management LLC increased its stake in shares of Plus Therapeutics by 72.5% during the 4th quarter. Geode Capital Management LLC now owns 1,402,794 shares of the company’s stock worth $719,000 after purchasing an additional 589,544 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Plus Therapeutics during the 4th quarter worth approximately $525,000. Altium Capital Management LLC purchased a new stake in shares of Plus Therapeutics during the 3rd quarter worth approximately $628,000. Finally, Virtu Financial LLC purchased a new stake in Plus Therapeutics in the fourth quarter worth $254,000. Institutional investors own 3.28% of the company’s stock.

Analyst Ratings Changes

PSTV has been the topic of several recent research reports. Lake Street Capital initiated coverage on shares of Plus Therapeutics in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $50.00 price target on the stock. Ascendiant Capital Markets dropped their price target on shares of Plus Therapeutics from $475.00 to $65.00 and set a “buy” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen raised shares of Plus Therapeutics to a “sell” rating in a research report on Saturday, April 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Tuesday, April 21st. Finally, D. Boral Capital reissued a “hold” rating on shares of Plus Therapeutics in a research report on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Plus Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $58.00.

About Plus Therapeutics

Plus Therapeutics is a clinical‐stage biopharmaceutical company specializing in the development of targeted radiotherapeutics for oncology. Its platform technologies leverage nanoliposomes and microspheres to deliver therapeutic radioisotopes directly to tumor sites. The company’s lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas, while its rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma and brain metastases.

The pipeline also includes investigational treatments for bone metastases, malignant pleural effusions and other hard-to-treat solid tumors.